Violation Tracker Industry Summary Page
Industry:
pharmaceuticals
Penalty Total since 2000:
$56,047,506,711
Number of Records:
944
Note:
The totals include only those entries matched to a parent company. The industry designation is the primary one for the parent's operations overall. The totals are adjusted to account for the fact that each parent's entries may include both agency records and settlement announcements for the same case; or else a penalty covering multiple locations may be listed in the individual records for each of the facilities. They are also adjusted to reflect cases in which federal and state or local agencies cooperated and issued separate announcements of the outcome. Duplicate or overlapping penalty amounts are marked with an asterisk in the individual records list below.
| Top 10 Parent Companies | Total Penalty $ | Number of Records |
|---|---|---|
| Purdue Pharma | $9,124,272,787 | 10 |
| GlaxoSmithKline | $7,822,200,258 | 34 |
| Merck | $5,615,085,581 | 80 |
| Pfizer | $4,660,896,333 | 71 |
| Johnson & Johnson | $4,248,447,763 | 58 |
| AbbVie | $3,203,142,507 | 49 |
| Teva Pharmaceutical Industries | $2,735,215,328 | 53 |
| Novartis | $2,526,283,570 | 39 |
| Mallinckrodt | $1,755,367,478 | 20 |
| Eli Lilly | $1,641,330,176 | 25 |
Individual Penalty Records:
Click on the company or penalty amount for more information on each case. Click on the parent name to reach the summary page for that parent company.
| Company | Parent | Primary Offense Type | Year | Agency |
Penalty Amount |
|---|---|---|---|---|---|
| Purdue Pharma LP | Purdue Pharma | fraud | 2020 | DOJ_CIVIL | $8,344,000,000 |
| GlaxoSmithKline Holdings (Americas) | GlaxoSmithKline | tax violations | 2006 | IRS | $3,400,000,000 |
| GlaxoSmithKline LLC | GlaxoSmithKline | off-label or unapproved promotion of medical products | 2012 | FDA | $3,000,000,000 |
| Pfizer Inc. | Pfizer | off-label or unapproved promotion of medical products | 2009 | FDA | $2,300,000,000 |
| Merck & Co., Inc. | Merck | tax violations | 2007 | IRS | $2,300,000,000 |
| Johnson & Johnson | Johnson & Johnson | off-label or unapproved promotion of medical products | 2013 | FDA | $2,200,000,000 |
| Mallinckrodt | Mallinckrodt | Controlled Substances Act violation | 2020 | MULTI-AG | $1,600,000,000 |
| Abbott Laboratories Inc. | AbbVie | off-label or unapproved promotion of medical products | 2012 | FDA | $1,500,000,000 |
| Eli Lilly and Company | Eli Lilly | off-label or unapproved promotion of medical products | 2009 | FDA | $1,415,000,000 |
| Cephalon, Inc. | Teva Pharmaceutical Industries | consumer protection violation | 2015 | FTC | $1,200,000,000 |
| Merck, Sharp & Dohme | Merck | off-label or unapproved promotion of medical products | 2011 | FDA | $950,000,000 |
| TAP Pharmaceutical Products Inc. | Takeda Pharmaceutical | False Claims Act and related | 2001 | DOJ_CIVIL | $875,000,000 |
| Pfizer Inc. | Pfizer | False Claims Act and related | 2016 | DOJ_CIVIL | $784,600,000 |
| Amgen Inc. | Amgen | off-label or unapproved promotion of medical products | 2012 | FDA | $762,000,000 |
| SB Pharmco Puerto Rico Inc. | GlaxoSmithKline | drug or medical equipment safety violation | 2010 | FDA | $750,000,000 |
| Serono, S.A. | Merck KGaA (EMD) | off-label or unapproved promotion of medical products | 2005 | FDA | $704,000,000 |
| Merck & Company | Merck | False Claims Act and related | 2008 | DOJ_CIVIL | $650,000,000 |
| Novartis Pharmaceuticals Corporation | Novartis | False Claims Act and related | 2020 | DOJ_CIVIL | (*) $642,000,000 |
| Amgen Inc. | Amgen | off-label or unapproved promotion of medical products | 2012 | MULTI-AG | (*) $612,000,000 |
| Allergan Inc. | AbbVie | off-label or unapproved promotion of medical products | 2010 | FDA | $600,000,000 |
| Abbott Laboratories and CG Nutritionals | Abbott Laboratories | False Claims Act and related | 2003 | DOJ_CIVIL | $600,000,000 |
| Indivior Solutions | Indivior Inc. | False Claims Act and related | 2020 | DOJ_CIVIL | $589,000,000 |
| Johnson & Johnson | Johnson & Johnson | off-label or unapproved promotion of medical products | 2013 | MULTI-AG | (*) $541,000,000 |
| AstraZeneca LP | AstraZeneca | off-label or unapproved promotion of medical products | 2010 | FDA | $520,000,000 |
| Bristol-Myers Squibb Company | Bristol-Myers Squibb | off-label or unapproved promotion of medical products | 2007 | DOJ_CIVIL | $515,000,000 |
| Ranbaxy USA Inc. | Sun Pharmaceuticals | drug or medical equipment safety violation | 2013 | FDA | $500,000,000 |
| Schering-Plough Corporation | Merck | drug or medical equipment safety violation | 2002 | DOJ_CIVIL | $500,000,000 |
| Wyeth Pharmaceuticals Inc. | Pfizer | off-label or unapproved promotion of medical products | 2013 | FDA | $490,900,000 |
| GlaxoSmithKline | GlaxoSmithKline | off-label or unapproved promotion of medical products | 2012 | MULTI-AG | (*) $477,792,391 |
| Mylan Inc. | Viatris | False Claims Act and related | 2017 | DOJ_CIVIL | $465,000,000 |
| Mylan Inc. | Viatris | False Claims Act and related | 2017 | MULTI-AG | (*) $465,000,000 |
| Purdue Frederick Company Inc. | Purdue Pharma | False Claims Act and related | 2007 | USAO | $461,900,000 |
| Schering-Plough Corporation | Merck | off-label or unapproved promotion of medical products | 2006 | USAO | $435,000,000 |
| Warner-Lambert | Pfizer | off-label or unapproved promotion of medical products | 2004 | FDA | $430,000,000 |
| Cephalon Inc | Teva Pharmaceutical Industries | off-label or unapproved promotion of medical products | 2008 | FDA | $425,000,000 |
| Novartis Pharmaceuticals Corporation | Novartis | off-label or unapproved promotion of medical products | 2010 | FDA | $422,500,000 |
| Janssen Pharmaceuticals, Inc. | Johnson & Johnson | off-label or unapproved promotion of medical products | 2013 | USAO | $410,000,000 |
| Novartis Pharmaceuticals | Novartis | kickbacks and bribery | 2015 | USAO | $390,000,000 |
| Wyeth Pharmaceuticals, Inc. | Pfizer | False Claims Act and related | 2016 | MULTI-AG | (*) $371,351,180 |
| Eli Lilly and Company | Eli Lilly | off-label or unapproved promotion of medical products | 2009 | MULTI-AG | (*) $361,828,456 |
| Actelion Pharmaceuticals US, Inc. | Johnson & Johnson | False Claims Act and related | 2018 | DOJ_CIVIL | $360,000,000 |
| AstraZeneca Pharmaceuticals LP | AstraZeneca | False Claims Act and related | 2003 | DOJ_CIVIL | $354,900,000 |
| Shire Pharmaceuticals LLC | Takeda Pharmaceutical | False Claims Act and related | 2017 | DOJ_CIVIL | $350,000,000 |
| Schering-Plough Corporation | Merck | kickbacks and bribery | 2004 | DOJ_CIVIL | $345,000,000 |
| Abbott Laboratories | AbbVie | off-label or unapproved promotion of medical products | 2012 | MULTI-AG | (*) $339,148,643 |
| Pfizer, Inc. | Pfizer | kickbacks and bribery | 2009 | MULTI-AG | (*) $331,485,170 |
| Bristol-Myers Squibb | Bristol-Myers Squibb | fraud | 2005 | USAO | $300,000,000 |
| Schering-Plough Corporation | Merck | kickbacks and bribery | 2004 | MULTI-AG | (*) $292,969,482 |
| Merck | Merck | False Claims Act and related | 2008 | MULTI-AG | (*) $290,000,000 |
| Teva Pharmaceutical Industries Ltd | Teva Pharmaceutical Industries | Foreign Corrupt Practices Act | 2016 | DOJ_CRIMINAL | $283,177,348 |
| Dey Inc. | Viatris | False Claims Act and related | 2010 | DOJ_CIVIL | $280,000,000 |
| Roxane Laboratories Inc. | Hikma Pharmaceuticals | False Claims Act and related | 2010 | DOJ_CIVIL | $280,000,000 |
| Celgene Corp. | Bristol-Myers Squibb | False Claims Act and related | 2017 | USAO | $280,000,000 |
| Purdue Pharma | Purdue Pharma | Controlled Substances Act violation | 2019 | OK-AG | $270,000,000 |
| Ranbaxy | Sun Pharmaceuticals | drug or medical equipment safety violation | 2013 | MULTI-AG | (*) $266,729,715 |
| Serono Inc. | Merck KGaA (EMD) | off-label or unapproved promotion of medical products | 2005 | MULTI-AG | (*) $262,000,000 |
| Wyeth Pharmaceuticals, Inc. | Pfizer | off-label or unapproved promotion of medical products | 2013 | MULTI-AG | (*) $257,400,000 |
| Teva Pharmaceutical Industries Limited | Teva Pharmaceutical Industries | Foreign Corrupt Practices Act | 2016 | SEC | $236,000,000 |
| Novartis Hellas S.A.C.I. et al. | Novartis | Foreign Corrupt Practices Act | 2020 | DOJ_CRIMINAL | $233,000,000 |
| Insys Therapeutics | Insys Therapeutics | False Claims Act and related | 2019 | DOJ_CIVIL | $225,000,000 |
| AstraZeneca Pharmaceuticals LP | AstraZeneca | off-label or unapproved promotion of medical products | 2010 | MULTI-AG | (*) $218,092,993 |
| United Therapeutics Corporation | United Therapeutics | False Claims Act and related | 2017 | DOJ_CIVIL | $210,000,000 |
| Elan Corporation PLC | Perrigo | off-label or unapproved promotion of medical products | 2010 | FDA | $203,000,000 |
| Merck Sharp & Dohme Corp. | Merck | off-label or unapproved promotion of medical products | 2012 | MULTI-AG | (*) $201,975,000 |
| Sandoz Inc. | Novartis | price-fixing or anti-competitive practices | 2020 | DOJ_ANTITRUST | $195,000,000 |
| Endo Health Solutions Inc. | Endo International | off-label or unapproved promotion of medical products | 2014 | FDA | $192,700,000 |
| Aventis Pharmaceuticals Inc. | Sanofi | False Claims Act and related | 2007 | DOJ_CIVIL | $190,000,000 |
| Warner-Lambert | Pfizer | off-label or unapproved promotion of medical products | 2004 | MULTI-AG | (*) $190,000,000 |
| Bristol-Myers Squibb | Bristol-Myers Squibb | False Claims Act and related | 2008 | MULTI-AG | (*) $187,000,000 |
| Janssen Pharmaceuticals, Inc. | Johnson & Johnson | off-label or unapproved promotion of medical products | 2012 | MULTI-AG | $181,000,000 |
| Novartis Corporation | Novartis | employment discrimination | 2010 | private lawsuit-federal | $175,000,000 |
| Endo Health Solution | Endo International | off-label or unapproved promotion of medical products | 2014 | MULTI-AG | (*) $173,000,000 |
| Teva Pharmaceuticals Inc. | Teva Pharmaceutical Industries | False Claims Act and related | 2010 | MULTI-AG | $169,000,000 |
| Forest Pharmaceuticals Inc. | AbbVie | off-label or unapproved promotion of medical products | 2011 | FDA | $164,000,000 |
| SB Pharmco Puerto Rico Inc. | GlaxoSmithKline | drug or medical equipment safety violation | 2010 | MULTI-AG | (*) $163,560,000 |
| Purdue Frederick Company Inc. | Purdue Pharma | False Claims Act and related | 2007 | MULTI-AG | (*) $160,000,000 |
| Johnson & Johnson | Johnson & Johnson | off-label or unapproved promotion of medical products | 2012 | TX-AG | $158,000,000 |
| Par Pharmaceuticals, Inc. | Endo International | False Claims Act and related | 2011 | MULTI-AG | $154,000,000 |
| GlaxoSmithKline | GlaxoSmithKline | False Claims Act and related | 2005 | DOJ_CIVIL | $150,000,000 |
| Bristol-Myers Squibb Company | Bristol-Myers Squibb | accounting fraud or deficiencies | 2004 | SEC | $150,000,000 |
| Forest Pharmaceuticals Inc. | AbbVie | False Claims Act and related | 2010 | USAO | $149,000,000 |
| Valeant Pharmaceuticals International, Inc. | Bausch Health | investor protection violation | 2017 | MULTI-AG | $145,000,000 |
| Hoffman-LaRoche | Roche | price-fixing or anti-competitive practices | 2000 | MULTI-AG | $142,494,000 |
| Abbott Laboratories Inc. | AbbVie | False Claims Act and related | 2010 | DOJ_CIVIL | $126,500,000 |
| Warner Chilcott PLC | AbbVie | off-label or unapproved promotion of medical products | 2015 | FDA | $125,000,000 |
| Cephalon | Teva Pharmaceutical Industries | consumer protection violation | 2016 | MULTI-AG | $125,000,000 |
| King Pharmaceuticals | Pfizer | False Claims Act and related | 2005 | DOJ_CIVIL | $124,000,000 |
| King Pharmaceuticals | Pfizer | False Claims Act and related | 2006 | MULTI-AG | (*) $124,000,000 |
| Johnson & Johnson | Johnson & Johnson | drug or medical equipment safety violation | 2019 | MULTI-AG | $120,000,000 |
| Mylan Pharmaceuticals and UDL Laboratories | Viatris | False Claims Act and related | 2009 | DOJ_CIVIL | $118,000,000 |
| Mylan Pharmaceuticals, Inc. | Viatris | False Claims Act and related | 2009 | MULTI-AG | (*) $118,000,000 |
| Johnson & Johnson | Johnson & Johnson | drug or medical equipment safety violation | 2019 | MULTI-AG | $116,860,000 |
| Cephalon Inc. | Teva Pharmaceutical Industries | off-label or unapproved promotion of medical products | 2008 | MULTI-AG | (*) $116,000,000 |
| Avanir Pharmaceuticals | Otsuka Pharmaceutical | False Claims Act and related | 2019 | DOJ_CIVIL | $115,874,895 |
| Novartis AG | Novartis | Foreign Corrupt Practices Act | 2020 | SEC | $112,800,000 |
| AstraZeneca | AstraZeneca | False Claims Act and related | 2018 | TX-AG | $110,000,000 |
| Sanofi-Aventis U.S. Inc. | Sanofi | False Claims Act and related | 2012 | DOJ_CIVIL | $109,000,000 |
| Mylan Laboratories et al. | Viatris | price-fixing or anti-competitive practices | 2000 | MULTI-AG | (*) $108,000,000 |
| GlaxoSmithKline, LLC | GlaxoSmithKline | kickbacks and bribery | 2014 | MULTI-AG | $105,000,000 |
| Novartis Pharmaceuticals Corp. | Novartis | kickbacks and bribery | 2020 | MULTI-AG | $103,000,000 |
| Mylan Laboratories, Inc. | Viatris | consumer protection violation | 2000 | FTC | $100,000,000 |
